

Programs

Indication

Discovery

IND Enabling Pre-Clinical

Phase I

Phase II - III

Oncology


IPT-001
HERV-K Cancer Immune Therapy
Ad19 + Ad5F35 expressing proprietary HERV-K

Prostate, then
Breast, Ovarian, & other Solid Tumors



IPT-001 + mRNA Booster
HERV-K Cancer Immune Therapy
Ad19 + Ad5F35 + mRNA w. proprietary HERV-K

Prostate, then
Breast, Ovarian, & other Solid Tumors



HERV-K Biomarkers, Companion Diagnostic for
disease progression, survival

Patient stratification



Aging

HERV-K and HERV-W Immune Therapy

Senescence

